Vast amounts of data were presented at the Esmo meeting over the weekend. Here is a roundup of Vantage’s analysis of the most crucial trials.
The first look at data from Roche’s tumour-agnostic project entrectinib look good, but not good enough to unseat Loxo and Bayer’s larotrectinib.
A dramatic extension in progression-free survival in Astrazeneca's Solo-1 study raises the prospect of improving cure rates in ovarian cancer, though the impact…
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.